To identify factors associated with persistence of human papillomavirus (HPV) DNA in the uterine cervix, 179 women who were 18-49 years old and who had normal cytologies and positive cer~ical HPV DNA tests at a routine periodic examination were analyzed. Among them, 91 (50.8%) remained HPV-positive a few months (mean, 11 weeks) later. Persistence was higher in women who had used oral contraceptives for ;::2 years (odds ratio, 3.9; 95% confidence interval, 1.5-10.3) compared with those who never used oral contraceptives or used them for <2 years. HPV types 16, 18, and 31/33/35 appeared more persistent (odds ratio, 2.5; 95% confidence interval, 1.0-6.2) than other types. Persistence seemed to increase with virus load and decrease with increasing interval between examinations.
appears high. The study was restricted to women who were not pregnant and were not in their menstrual period, since biopsies of the uterine cervix may be problematic during pregnancy, and cervical smears may be more difficult to obtain and interpret during menstrual periods. Participants were also required to have an intact uterus.
Initial examination. At the initial visit, a sample of cells from the ectocervix and transitional zone was collected with a Dacrontipped sampler for HPV testing. A cervicovaginal smear was taken. Trained cytotechnologists evaluated cervicovaginal smears according to the Bethesda classification system [15, 16] .
Scrapes obtained with the Dacron-tipped sampler were placed in 15-mL plastic centrifuge tubes containing 2 mL of PBS. These tubes were collected daily from the clinics, brought to the laboratory, and refrigerated. Cells ofthe saline samples were resuspended in 200 J-tL of K buffer [17] . This mixture was digested at 55°C for 1 h and subsequently heated at 95°C for 10 min to inactivate the protease. HPV DNA was amplified by polymerase chain reaction (PCR). Using Manos' consensl,lS primers MY09 and MY11, PCR detected target DNA of the HPV L1 region [18, 19] . Precautions were taken to prevent cross-contamination with amplified DNA sequences [20] . Ethidium bromide-stained gels were examined after electrophoresis to detect the presence of 450-bp fragments generated by those primers.
PCR products were hybridized under stringent conditions with specific radiolabeled HPV DNA probes MY12 (type 6), MY13 (type 11), MY14 (type 16), WD74 (type 18), WD128 (type 31). MY16 (type 33), and MY115 (type 35) [21] . Membranes were hybridized and washed according to previously described conditions [18] . Positive (HPV clones 16 and 18) and negative controls (without DNA or with human DNA extracted from the K562 cell line) were used in every series of tests. Molecular hybridization under nonstringent conditions with HPV plasmid types 6, 16, and 18 (supplied by H. zur Hausen and L. Gissmann, Heidelberg, Germany) was also done on the amplified material. Specimens used for HPV detection were tested for human ,B-globin gene DNA by PCR to confirm the presence of adequate human DNA in the sample.
Women were considered to be HPV DNA-positive if HPV amplification products were visible on ethidium bromide-stained gels and hybridization was positive, if molecular hybridization alone was positive, or if gel alone was positive. Specimens were processed and assessed in a blinded fashion.
Subsequent examination. Women were referred to the colposcopy clinic of Saint-Sacrement Hospital for a second evaluation if they had DNA-based evidence of cervical HPV infection or had an abnormal cytology result (low-or high-grade squamous intraepitheliallesion). At the colposcopy clinic, sampling was done of a specimen to reassess the presence ofHPV DNA, a cervicovaginal smear was obtained, and colposcopy and colposcopy-directed biopsies of lesions were done. PCR and cervicovaginal smears were reassessed using the same methods as before but without knowledge of previous results.
Analysis. A total of 1753 women were recruited, including 1599 with normal cervicovaginal cytologies (including atypical squamous cells of undetermined significance [15, 22] ) and with an adequate sample of DNA for HPV testing. Among these 1599, 285 (prevalence, 17.8%; 95% confidence interval (CI), 15.9%-19.7%) presented with HPV DNA in cervical epithelium.
A total of 106 of these 285 subjects could not be included in the present analysis. The 51 who were positive by nonstringent hybridization only were not asked to come for colposcopy because the interval between screening and the time nonstringent hybridization was done exceeded 6 months for most participants. In addition, physicians' permission to contact subjects was not obtained for 10 cases, and 13 could not be located. Moreover, 23 declined the invitation for a colposcopic examination. Finally, the cervical sample obtained at colposcopy contained insufficient DNA for HPV testing in 9 subjects.
Thus, this analysis focuses on the 179 infected women with normal cytologies for whom all data were available: 101 were HPV DNApositive by examination of ethidium bromide-stained gel and molecular hybridization, 60 were HPV DNA-positive by hybridization only, and 18 were positive by examination of the gel only.
In the analysis, computation of the confidence intervals around proportions is based on the formula for the variance ofthe binomial distribution. To examine the relation of exposures to persistence of HPV DNA, the proportion of women with persistently detectable HPV DNA in different categories i of exposure (Pi) 
Results
Characteristics of the 179 women who were HPV DNApositive at initial examination are shown in table 1. Among these women, 91 remained HPV DNA-positive at reexamination (table 2) . Thus, the percentage of women with persistently detectable HPV DNA over a period of a few months (mean, 10.5 weeks) reached 50.8% (95% CI, 43.5%-58.1 %). For the 106 women initially positive for cancer-associated HPV DNA types 16, 18, and 31/33/35 (excluding the 5 women with mixed infections and 68 who were infected with other HPV types), persistence reached 50.0% (95% CI, 40.5%-59.5%). This per- centage is lower when persistence is defined as detection of HPV DNA ofthe same group of viruses at the two examinations (persistence, 31.1%; 95% CI, 22.3%-39.9%). Several factors were found to be related to persistence ofdetectable HPV DNA (table 3) . Persistence was more frequent among young than among older women. As the lifetime number of sex partners increased, the likelihood of persistence increased. The proportion of women with persistent HPV DNA was 17.7% among those who reported having had only I sex partner but increased to 66.7% among those reporting~8 partners. Duration of oral contraceptive use also tended to be associated with increased likelihood of persistence. Persistence was higher in women who had used oral contraceptives for~2 years (adjusted OR, 3.9; 95% CI, 1.5-10.3) compared with those who reported never having used oral contraceptives or who used such contraceptives for a shorter period of time. Finally, persistence of detectable HPV DNA tended to be higher among women positive for cancerassociated types 16, 18, or 31/33/35 and among those who, at initial examination, had high virus load (i.e., those who were HPV DNA-positive by examination of the ethidium bromide-stained gel compared with women who were positive only by hybridization of amplified material). Time interval between examinations, education, marital status, age at first intercourse, number of pregnancies, history of gynecologic infection, condom use, smoking, and alcohol drinking showed little or no relation to persistence of HPV DNA either in the univariate analysis or once adjustments were made for the factors presented in table 3. A history of low-or high-grade CIN was related to persistence in the univariate analysis (crude OR, 4.8; 95% CI, 1.6-15.0). When this association was adjusted for factors presented in table 3, the OR was substantially reduced (adjusted OR, 2.5; 95% CI, 0.6-10.0).
In the above analyses, persistent detection of HPV DNA was defined as detection of HPV DNA in cervical samples obtained at reexamination irrespective ofthe type ofHPV DNA found. Thus, analyses were repeated using a more stringent approach for the definition of persistence. This reanalysis focused on the 106 women who initially were positive for either HPV-16, -18, or -31/33/35. HPV DNA was judged to be persistent only if the viral type found at reexamination was similar to that detected initially. The relations with age, duration of oral contraceptive use, history of condyloma in sex partners, and virus load remained clear, although CIs tended to be wider and to include the null value (table 4). Persistence increased with number of sex partners in the crude analysis, but this association appeared to be explained when adjustments were made for confounding factors. Finally, an association of persistence with interval between examinations emerged. Among women examined < 7, 7-10, 11-14, and~15 weeks after their initial visit, the percentages with persistent HPV DNA were 55.0%, 43.2%, 25.0%, and 6.1 %, respectively. Although strong, this relation was not statistically significant. No other new association emerged.
Discussion
In many women, HPV DNA can be detected early but not later or later but not early, while in others, HPV DNA can be persistently detected [6] [7] [8] [9] [10] [11] [12] [13] [14] . For instance, Schneider et al. [9] assessed the presence of HPV-16 DNA every 5 weeks for 1 year in 21 women with normal cytology results at entry. Over 10 visits, 14 women (66.7%) were HPV-16 DNA-positive at least once. However, HPV-16 DNA was not detected at least once in all of these subjects. The 27 women studied by Moscicki et al. [13] were initially HPV DNA-positive and were examined on at least three occasions. Of them, only 3 (11 %) remained consistently positive for the viral type detected at the first visit. Hildesheim et al. [14] tested women twice. Among the 102 who were HPV DNA-positive at the initial examination, 64 (63%) were again positive at reexamination. Among the 86 for whom specific HPV types were detected at the initial evaluation, only 40.7% had persistently detectable HPV DNA of the same type at reexamination.
Interpretation of these observations is impeded by the limitations of the tests used. Earlier studies were based on filter in situ hybridization and Southern blot hybridization without PCR amplification. Thus, lack of sensitivity of these assays could explain, at least in part, the variability in HPV DNA detection. However, the three reports mentioned above made use ofPCRbased approaches. Even though these approaches can detect very low viral copy numbers, substantial variability in test results continued to be observed.
Moreover, measures focused on persistence of detection of HPV DNA, which may not be equivalent to persistence of HPV infection. Continued detection of HPV DNA of the same viral type at several points close in time is likely to reflect persistence of the infection, but the possibility of repeated reinfection with the same virus is difficult to eliminate.
Given the limitations oftesting procedures in use, the interpretation of the apparent disappearance ofHPV DNA is also problematic. Although such disappearance may reflect eradication of the infection, viral DNA may still be present in the epithelium but become undetectable for other reasons. The approaches used to sample cervical cells and detect viral DNA may still not be sufficiently sensitive [23] . PCR coupled with hybridization may have greater limitations than expected when used in field studies in which the quantity and quality of the sample vary from subject to subject and from examination to examination. Alternatively, in some phases of the natural history of HPV infection, HPV DNA may not be detected if the virus is present only in cells of the deeper layers of the epithelium, which are not easily sampled by cervical swabs or cervicovaginal lavages.
Finally, identification at reexamination of HPV types that were undetected initially may not always represent new infections. It seems possible that in many instances, these newly detected viruses may have been present initially but the test may have failed to detect their DNA. In the present study, this possibility appears likely, given the short interval between examinations.
In addition to the uncertainties related to the limitations of HPV testing procedures, studies of persistence of HPV DNA can suffer from uncertainties common for follow-up studies. For instance, in the present analysis, 51 subjects who were HPV DNA-positive by hybridization only were not invited for a follow-up examination. Since persistence appeared somewhat lower in these subjects, these exclusions may have led to some overestimation of persistence. Moreover, 23.5% of the 234 subjects invited for a follow-up examination could not be seen. Such partial participation can introduce confounding, although an effort was made to control such confounding through statistical modeling.
Likelihood of persistence of detectable HPV DNA appears to depend on characteristics of the infection. Our data suggest that HPV DNA positivity may be more persistent for cancerassociated HPV types 16, 18, and 31/33/35. This observation is consistent with that of Hildesheim et al. [14] .
Moreover, persistent detection of HPV DNA appeared to increase with the amount of HPV DNA present in the initial cervical specimen. When the amount of amplified HPV DNA was sufficient to be visible on an ethidium bromide-stained gel, the odds of persistence were greater than when the amount was insufficient to be visible on the gel. Moscicki et al. [13] also reported increased persistence of HPV DNA in high-compared with low-level infection. Indicators of the amount of HPV DNA used in these reports are quite crude and likely to be associated with some degree of misclassification. Thus, true associations of extent of infection with persistent detection ofHPV DNA may be stronger than those observed. In some reports, measures of virus load appeared to be related to risk ofCIN [24] [25] [26] and cervical cancer [27, 28] . Development and validation of HPV testing strategies that would allow a better assessment of virus load appear increasingly relevant.
In this study, persistence of type-specific HPV DNA decreased as time since initial examination increased. This reduction is particularly remarkable given the short time interval between the two examinations. Detection of HPV DNA decreased substantially with the interval since entry in subjects studied by Hildesheim et al. [14] , who considered longer intervals between examinations. In contrast, apparent lack of association of persistence with interval between examinations was reported by Moscicki et al. [13] .
In our data, use of oral contraceptives for at least 2 years was related to increased persistence of detectable HPV DNA, suggesting that persistence might be regulated, at least inpart, by sex hormones. Some epidemiologic and laboratory observations tend to support this possibility. Detection of HPV DNA may be higher in pregnant than nonpregnant women [29] [30] [31] [32] [33] . Progesterone/glucocorticoid response elements have been identified in regulatory regions of the DNA of several HPV types [34, 35] . Progesterone and dexamethasone increase the expression of HPV-16 DNA transfected in human cervical keratinocytes, while the antiprogestin RU 486 can inhibit this hormoneinduced expression [36] . Finally, glucocorticoids increase the efficiency of immortalization of foreskin keratinocytes by HPV-16 [37] .
Although we had no data on immune function, cell-mediated immunity should also be considered a possible determinant of persistence ofHPV DNA. Reduction of CD4 lymphocyte count was related to increase in the persistence of detectable HPV DNA in a group of human immunodeficiency virus type 1-seropositive women [38] . Increased frequency of progression and recurrence of HPV-related CIN was also seen with reduction of CD4 lymphocyte count in human immunodeficiency virus-infected patients and with increased duration of immunosuppression in allograft recipients [39] .
